

Dr. Kenneth Eilertsen, CEO and President of NuPotential, Inc., attended the 3rd World Epigenetics Summit, held July 24 – 26, 2012 in Boston, Massachusetts. The Summit is the world's largest commercially focused epigenetics meeting. The field of epigenetic research has enormous potential to progress diagnosis and therapy in oncology and the wider disease spectrum. The pan-disease potential of epigenetic based drugs is encouraging floods of investment as basic research is being translated into clinical utility.

NuPotential, Inc., a Baton Rouge based biotechnology company, is pioneering the discovery and development of epigenetic drugs. These novel compounds modulate epigenetic targets and their processes, for the treatment of cancer, metabolic, inflammatory and neurodegenerative disease. Dr. Eilertsen founded NuPotential, Inc. in 2004 based on his discoveries linking small molecule epigenetic pathway modulators and cellular reprogramming.